Cancer somatic mutations can generate neoantigens that distinguish malignant from normal cells 1-7 . However, the personalized identification and validation of neoantigens remains a major challenge. Here we discover neoantigens in human mantle-cell lymphomas by using an integrated genomic and proteomic strategy that interrogates tumour antigen peptides presented by major histocompatibility complex (MHC) class I and class II molecules. We applied this approach to systematically characterize MHC ligands from 17 patients. Remarkably, all discovered neoantigenic peptides were exclusively derived from the lymphoma immunoglobulin heavy-or light-chain variable regions. Although we identified MHC presentation of private polymorphic germline alleles, no mutated peptides were recovered from non-immunoglobulin somatically mutated genes. Somatic mutations within the immunoglobulin variable region were almost exclusively presented by MHC class II. We isolated circulating CD4 + T cells specific for immunoglobulinderived neoantigens and found these cells could mediate killing of autologous lymphoma cells. These results demonstrate that an integrative approach combining MHC isolation, peptide identification, and exome sequencing is an effective platform to uncover tumour neoantigens. Application of this strategy to human lymphoma implicates immunoglobulin neoantigens as targets for lymphoma immunotherapy.
specific for human leukocyte antigen (HLA)-DR, a class II MHC molecule, and analysed by LC-MS/MS. This strategy identified over 24,000 unique MHC-I-associated peptides and over 12,500 unique MHC-II-associated peptides (Fig. 1b ). Both MHC-I and MHC-II peptide repertoires demonstrated length distributions consistent with those expected for each class ( Fig. 1c and Extended Data Fig. 1a, b ). Furthermore, MHC-I peptides showed the expected reduced amino-acid complexity at anchor residue positions (Extended Data Fig. 1c ) and agreed with a widely used binding affinity model (Extended Data Fig. 1d-f ).
Through whole-proteome analysis of two MCL cell lines, we found MHC-I and MHC-II presentation was significantly biased towards abundant proteins (Extended Data Fig. 2) . In contrast, we found mutated proteins tended to be significantly less abundant than average. We found a high degree of overlap among genes presented by MHC across patients (Extended Data Fig. 3a, b ). However, the specific peptides we recovered were generally private to each individual, with the exception of patients who shared MHC-I and/or MHC-II alleles (Extended Data Fig. 3c-f ), further confirming MHC as the source of the recovered peptides. Among the recurrently presented genes were members of the B-cell receptor signalling pathway including IGHM, CD79B, BTK, LYN, SYK, MS4A1 (CD20), and CD22, which showed significant enrichment ( Fig. 2a and Extended Data Fig. 3g ).
There were 13-175 non-synonymous somatic mutations per patient exome, including genes known to be recurrently mutated in MCL such as Ig variable regions, TP53, CCND1, ATM, UBR5, SMARCA4, NOTCH1, FAT4, TRAF2, and WHSC1 (refs 17, 18) ( Fig. 2b ). We also identified novel genes as recurrently mutated in MCL including PBRM1 and SMARCB1, with the latter gene previously found to be mutated in a single MCL patient 19 . Most non-synonymous mutations occurred in genes not characteristically expressed in MCL 20 (Fig. 2c ). Among expressed genes bearing coding mutations, we found 46% with at least one peptide presented by either class I or class II MHC, suggesting active processing of these mutated proteins. However, with the exception of peptides derived from Ig genes, the MHC-presented peptides were derived from the non-mutated regions of these genes, as exemplified by the two most frequently mutated non-Ig genes, TP53 and CCND1 (Fig. 2d ).
We recovered neoantigen peptides from 13 genes, all of which were derived from Ig variable regions. To test whether the lack of non-Ig neoantigens was due to technical limitations in recovering private peptide variants, we assessed the recovery of peptides encoded by heterozygous germline single nucleotide polymorphisms (SNPs) for each patient. This analysis revealed significantly greater presentation of LETTER RESEARCH germline versus somatic allelic variants across the genome (P < 0.001, Extended Data Fig. 4 ). To determine whether our approach was insensitive in detecting clinically significant neoantigens, we additionally assayed eight patients' CD8 T-cell responses against computationally predicted HLA-A2 restricted neoantigens with peptide-MHC tetramers (Extended Data Fig. 5 ). No immune responses were detected against any of the 108 putative neoantigens tested.
The Ig heavy chain was presented by both MHC-I and MHC-II in all 17 patients (Fig. 2b ). MHC-I and MHC-II displayed strikingly distinct antigen presentation patterns from this protein. Peptides presented by MHC-I mapped to the Ig constant regions (199 peptides, Supplementary Note 1 and Supplementary Table 1 ), but there were few peptides recovered from the Ig variable regions (eight peptides) ( Fig. 3a) . In contrast to MHC-I, antigen presentation of Ig by MHC-II was clustered within the variable region ( Fig. 3a) . Specifically, ~ 93% of MHC-II-bound peptides (105/113) spanned the junction of complementarity-determining region 3 (CDR3) and framework region 3 (Fig. 3a) . Nearly half of the peptides presented by MHC-II from this hotspot were neoantigens created by somatic hypermutation or V(D)J gene rearrangement (52/105 peptides, 49.5%) ( Fig. 3b and Supplementary Table 2 ). In contrast, only a single non-germline peptide was recovered from MHC-I. Peptides derived from light-chain variable regions showed similar profiles: 14 neoantigen peptides formed via somatic hypermutation were presented by MHC-II, but none by MHC-I ( Fig. 3c ). Using the Raji lymphoma cell line, we tested whether our approach did not detect MHC-I-restricted Ig neoantigens as a result of technical obstacles. We ectopically expressed an MHC-I allele with high predicted affinity for Raji Ig neoantigens. Antigen presentation profiling of the resultant Raji cells revealed three Ig neoantigens, thus confirming our ability to recover MHC-I Ig neoantigens (Extended Data Fig. 6 ).
To validate that neoantigens are true HLA-DR ligands, we synthesized neoantigen peptides from three patients with an HLA-DR* 0401 allele and confirmed their affinity for HLA-DR by exchange onto recombinant HLA-DR* 0401 molecules for five of the six tested peptides (Extended Data Fig. 7 ). We next determined whether these patients harboured T cells that recognized their autologous Ig neoantigens. Neoantigen peptide-HLA-DR* 0401 tetramers revealed corresponding neoantigen-specific peripheral blood CD4 T cells in one of three patients tested (Fig. 4a ). These CD4 + T cells seemed to be memory T cells because they lacked CD45RA expression, but they also lacked PD-1 expression, which has been associated with neoantigen-specific T cells in patients with melanoma 21 (Extended Data Fig. 8a ). Tetramer-binding T cells were sorted as single cells for sequencing of T-cell receptor (TCR) α -and β -chains, and single-cell gene expression phenotyping 22 . Of 79 cells from which TCR sequences were obtained, we found eight derived from a single dominant T-cell clone, and three from a second clonotype ( Fig. 4b ). Neither clone was seen among 192 analysed cells that did not bind the neoantigen tetramer. All cells expressed GATA3 and RORC, consistent with a Th 2 /Th 17 -skewed phenotype, and a subset also expressed granzyme B (Fig. 4b ). We next profiled this patient's neoantigen-specific T cells following autologous tumour vaccination (Fig. 4c, top) . TCR repertoire sequencing of peripheral blood T cells collected before and after the immunizations revealed that both neoantigen-specific T-cell clones were induced by vaccination (Fig. 4c, bottom) .
We next explored the therapeutic potential of patient-derived neoantigen-specific T cells. In a second patient, we recovered neoantigenspecific CD4 T cells, identified by CD137 expression, after stimu lation with autologous lymphoma Ig neoepitopes ( Fig. 4d ). We expanded these isolated T cells ex vivo and found they produced both IL-4 and granzyme in response to lymphoma neoepitopes, suggesting potential cytolytic function as previously described 3, 23 (Fig. 4e and Extended Data Fig. 8b, c) . Remarkably, we found these CD4 neoantigen-specific T cells could mediate cell killing of autologous lymphoma cells ( Fig. 4f ). Autologous Epstein-Barr virus (EBV)-transformed normal B cells that lacked the lymphoma neoantigen were unaffected, further demonstrating the antigen specificity of these T cells (Fig. 4f) . Similarly, pathogen-specific T cells that were purified and expanded in parallel were unable to kill lymphoma cells (Extended Data Fig. 9 ). 
LETTER RESEARCH
The unexpected bias against Ig variable-region presentation by MHC-I has important biological and therapeutic implications. Immunoediting represents one possible explanation for the observed bias 24, 25 . Although we found the lymphoma Ig sequences included numerous variable-region peptides with predicted high affinity for self-MHC-I, none were measured with our direct profiling (Extended Data Fig. 10 ). It remains unclear how primary lymphoma cells could avoid presenting high-affinity Ig variable-region peptides on MHC-I, while peptides derived from the constant region are prominently presented (Supplementary Note 2 and Supplementary Table 3 ).
Whereas the lack of MHC-I Ig variable-region presentation may represent a method of immune evasion, the contrasting frequent presentation of variable-region peptides by MHC-II suggests that Ig neoantigen recognition by CD4 does not inhibit lymphoma development. Mouse models have suggested that such presentation may serve to promote lymphomagenesis via cognate CD4-expressing helper T cells 26 . While Ig neoantigen-specific T cells displayed a Th2-like phenotype similar to these mouse models, they could nevertheless be engaged and expanded, and they demonstrated anti-tumour functions. Predicted neoantigens
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These findings also inform upon the previous experience with idiotype therapy. Idiotype vaccines seemed to provoke predominantly CD4 and/or humoral responses, consistent with our finding of selective MHC-II presentation of Ig antigens and CD4 Ig neoantigen-specific T cells 27, 28 . Clinical trials of vaccine therapy targeting lymphoma Ig variable regions showed early promise, but three independent phase III trials of idiotype vaccine found either modest or no overall clinical benefit [29] [30] [31] . Nevertheless, the subgroup of patients who generated immune responses were noted to derive substantial benefit 30 . Our results suggest that MHC presentation of variable-region epitopes is not equivalent across all individual lymphomas, raising the possibility that the patients who benefited from idiotype vaccination were those with active presentation of their Ig neoepitopes.
The number of somatic mutations, and therefore potential neoantigens, has been posited as a predictor of immune checkpoint response in malignancies with high mutational burden, such as lung cancer and melanoma 4, 32, 33 . Neoantigen discovery based on mass spectrometry has successfully identified MHC class I neoantigens from specimens with large mutation burdens, including cancer cell lines 13 and melanoma 11, 12 . By incorporating MHC class II ligands into our analysis, we uncover a different category of lymphomaspecific neoantigens. We find that, apart from Ig, mutated antigens are not prominently presented as MHC epitopes in MCL, similar to other haematological malignancies with low to moderate mutation burden 8, 9, 14 . It remains unclear whether the lack of recovered MHC neoantigens from primary human tumours reflects their true absence or a limitation of our method in detecting rare epitopes. Nevertheless, our findings suggest that the epitopes uncovered through direct, proteomic antigen profiling represent actionable antigen targets for T-cell therapy. Here, we leverage our ability to recover precise CD4 neoantigens to discover and augment the cytotoxic potential of the neoantigen-specific CD4 + T cells. Our results suggest that expansion of endogenous Ig neoantigen-specific CD4 + T cells may represent a viable treatment strategy for lymphoma. We demonstrate that by integrating genomic and proteomic analysis, antigen presentation profiling effectively identifies clinically relevant tumour antigens, and 

METHODS
No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. Tumour specimens. All specimens were obtained with informed consent in accordance with the Declaration of Helsinki and this study was approved by Stanford University's Administrative Panels on Human Subjects in Medical Research. Samples were collected from patients with untreated MCL by excisional lymph node biopsy, or splenectomy, or peripheral blood leukapheresis, and cryopreserved. Vaccine trial. Patient MCL041 was treated as part of an ongoing clinical trial of tumour vaccination (NCT00490529). Vaccine was prepared by ex vivo culture of circulating autologous lymphoma cells in AIM-V media and human AB-negative sera containing 3 μ g/ml PF-3512676 (CpG molecule) for 72 h. Cells were then irradiated with 200 Gy and cryopreserved. The patients were treated with induction chemotherapy and those with a complete remission then received a series of three weekly autologous tumour vaccinations. Leukapheresis was used to collect peripheral blood mononuclear cells before and after the series of vaccinations. Cell lines. JEKO and L128 MCL lines were originally obtained from the Lymphoma Research Foundation/Mantle Cell Lymphoma Consortium American Type Culture Collection (ATCC) cell line resource, tested for mycoplasma, and authenticated by STR profiling. Cell lines were grown according to ATCC recommendations. Exome sequencing. Tumour whole-exome sequencing was performed for 17 patients and the JEKO and L128 MCL cell lines as described previously 15, 16 . Tumour DNA was collected from either peripheral blood or lymph node biopsy. Tumour cells were purified by either flow cytometry or by magnetic bead purification for CD19 expression, or in some cases were not purified if the biopsy sample had ≥ 90% tumour purity. Germline DNA was obtained either from peripheral blood collected at time of complete remission or by fluorescenceactivated cell sorting (FACS) of CD3 + T cells from the initial tumour specimen. DNA and RNA were extracted from fresh single-cell suspensions using a Qiagen Allprep kit (Qiagen). Library preparation and exome capture were performed as previously described 16 . Next-generation sequencing libraries were prepared using KAPA Libarary Preparation kits (KAPA Biosystems). Briefly, 100 ng to 1.5 μ g of DNA per sample was sheared by sonication using a Covaris S-series instrument (Covaris). Sheared DNA was end-repaired according to the manufacturer's protocol and ligated with Illumina sequencing adaptors overnight at 16 °C. Adaptor-ligated product was enriched using eight to ten cycles of PCR with Phusion High-Fidelity PCR Master Mix (New England Biolabs), and size-selected using Agencourt Ampure XP beads (Beckman Coulter). Purified libraries were evaluated for size distribution using a BioAnalyzer High-Sensitivity DNA kit (Agilent), and quantified using spectrophotometry and a Qubit dsDNA HS assay (Invitrogen). Next-generation sequencing libraries were pooled and enriched for coding sequences using the SeqCap EZ Exome version 3.0 capture reagent (NimbleGen). Hybrid captures were performed according to the manufacturer's protocol, with all 47 °C steps conducted on a thermal cycler to ensure maximal temperature stability. Pooled libraries were amplified post-enrichment using six to eight cycles of PCR. Illumina sequencing services were performed by the Stanford Center for Genomics and Personalized Medicine, with 101-base-pair paired-end reads on a HiSeq 2000 instrument (Illumina) loading one capture pool per lane. Exome sequencing achieved a median depth of coverage over this region 94× in purified tumour B cells and 71× in germline samples. Variant calling and annotation. Raw sequences were demultiplexed and adaptor sequences trimmed. Reads were aligned to UCSC hg19 reference genome with the BWA mem aligner 34 and duplicate reads were removed. Single-nucleotide variant (SNV) and indel variants were called by VarScan2 (ref. 35 ) using reads with mapping quality > 10, minimum base quality > 20, minimum variant frequency 0.1, minimum of three variant reads, strand bias < 90%, minimum normal coverage at least six reads, and minimum tumour coverage at least eight reads. High-confidence somatic SNVs were then realigned around indels by Varscan2 and filtered using the false-positive filter script fpffilter.pl 36 . Variants were annotated and coding changes were predicted using Annovar 37 . Germline SNPs were called using VarScan2 with the above parameters. For cell lines, SNPs were assigned as germline if they were present in the NCBI dbSNP137 database. Neoantigen prediction. Coding variants were annotated to provide the corresponding mutated protein sequences using Annovar. Patient HLA alleles were extracted from sequencing of autologous normal cells using Phlat 38 . Neoantigen predictions were performed with NetMHC 3.4 (ref. 39) or, when the HLA allele was not included in the NetMHC model, NetMHCpan2. 8 (ref. 40) . Unless otherwise specified, peptides with predicted half-maximum inhibitory concentrations (IC 50 ) < 500 nM were considered neoantigens. Targeted Ig variable-region sequencing. Sequencing of Ig heavy and light chains was performed using modification of the BIOMED-2 protocol to reliably sequence the full-length variable region 41 . Tumour RNA was used to create complementary DNA (cDNA) using Superscript Reverse Transcriptase (ThermoFisher Scientific) according to standard protocol using random hexamers. PCR was performed with Kapa HiFi HotStart ReadyMix (Kapa Biosystems) with an annealing temperature of 68-70 °C using a mix of forward V-leader family primers and a reverse primer in the constant region ( Supplementary Table 4 ). PCR products were purified by agarose gel electrophoresis and extraction. PCR products were sequenced by Sanger sequencing either directly or after subcloning into the pCR-Blunt vector (ThermoFisher Scientific). VH usage and germline homology was determined using IMGT, the international ImMunoGeneTics information system (http://www. imgt.org) 42 . Generation of custom reference proteome databases. Two protein-sequence databases were constructed. Both were built upon the human proteome UniprotKB database including Swiss-Prot and TrEMBL databases (version May 2015) with common contaminant protein sequences included (for example, Staphylococcus protein A). The first was a somatic personalized database which included predicted mutated peptides inferred from somatic SNVs and indels from exome sequencing, as well as the lymphoma-specific IgVh and light-chain variable sequences as inferred from Ig V(D)J sequencing. The second database consisted of the same human proteome UniProt database but with added peptides derived from patient-specific coding, heterozygous SNPs, and cell-line-specific SNPs. Personalized entries consisted of the mutated amino acid(s) with flanking 21 amino acids both amino (N)-terminal and carboxy (C)-terminal to the mutated residue(s). Reversed 'decoy' protein sequences were appended to both of these databases for 'target-decoy' error estimation 43 . Purification of HLA peptides from cells. MHC class I and class II peptidomes were extracted from the MCL tumours of 17 patients and from two cell lines (JEKO, L128). The MHC class I or MHC class II molecules were isolated and the associated peptides extracted as previously described 44, 45 with some modifications. Before lysis, all cells were washed twice with PBS. For all patient samples, 1 × 10 8 cells were lysed per MHC preparation, while for the cell lines 1 × 10 8 and 1 × 10 9 cells were used to evaluate the extent to which limited input material may reduce the sensitivity ligand detection. In brief, cells were lysed for 20 min on ice in 20 mM Tris-HCl (pH8), 150 mM NaCl, 1% (w/v) CHAPS, 0.2 mM PMSF, 1× Halt Protease, and Phosphatase Inhibitor Cocktail (ThermoFisher Scientific) supplemented with complete Protease Inhibitor Cocktail (Roche). The lysate was subjected to centrifugation (2 × 30 min, 13,200 r.p.m. at 4 °C) and the resulting supernatant was pre-cleared for 30 min using rProtein A Sepharose Fast Flow beads (GE Healthcare). For all MHC-1 immunoprecipitations, the pre-cleared lysate was incubated with the pan HLA-A-, B-, and C-antibody W6/32 (purified in-house from hybridoma provided by B. Mellins and with Ig produced by Genentech 46 ) coupled to rProtein A Sepharose Fast Flow beads for 5 h at 4 °C. For MHC-II captures, the pre-cleared lysate was incubated with the HLA-DR-specific antibody L243 (produced and purified by Genentech from our hybridoma) 47 coupled to rProtein A Sepharose Fast Flow beads for 5 h at 4 °C. After immunoprecipitation, the beads were washed with TBS (pH 7.4) and peptides were eluted from the purified MHC molecules using 10% acetic acid. Eluted peptides were further purified with a 10 kDa molecular weight cut-off size filter, followed by a concentration step using vacuum centrifugation, de-salted on C18-based STAGE tips 48 . Peptides were lyophilized and stored at − 80 °C until LC-MS/MS analysis. Mass spectrometry analysis of HLA-associated peptides. For MS analysis, isolated peptides were reconstituted in 0.1% formic acid and analysed on an LTQ Orbitrap Elite mass spectrometer (Thermo Fisher Scientific) in three replicate injections of 25% of the total specimen amount. Samples were separated by capillary reverse-phase chromatography on an 18 cm reversed-phase column (100 μ m inner diameter, packed in-house with ReproSil-Pur C18-AQ 3.0 m resin (Dr. Maisch)) over a total run time of 160 min using a two-step linear gradient with 4-25% buffer B (0.2% (v/v) formic acid, 5% DMSO, and 94.8% (v/v) acetonitrile) for 120 min followed by 25-40% buffer B for 30 min using an Eksigent ekspert nanoLC-425 system (SCIEX, Framingham, Massachusetts, USA). Three injections were made per sample to utilize multiple fragmentation modes (HCD (higherenergy collisional dissociation) or CID (collision-induced dissociation)). The third injection was performed with CID including singly charged species. Acquisition was executed in data-dependent mode with the full MS scans acquired in the Orbitrap mass analyser with a resolution of 60,000 and m/z scan range 340-1,600. The top ten most intense ions were then selected for sequencing and fragmented in the Orbitrap mass analyser at a resolution of 15,000 (full width at half maximum). Data-dependent scans were acquired from precursors with masses ranging from 700 to 1,800 Da for all MHC class 1 samples and from 700 to 2,750 Da for MHC class II samples. Precursor ions were fragmented with a normalized collision energy of 35% and an activation time of 5 ms for CID and 30 ms for HCD. Repeat count was set to 2 and fragmented m/z values were dynamically excluded LETTER RESEARCH from further selection for a period of 30 s. The minimal signal threshold was set to 500 counts. Computational identification of HLA peptides from mass spectra. All tandem mass spectra were queried against personalized somatic and personalized germline proteome databases described above using both SEQUEST 49 and PEAKS DB search engines (PEAKS Studio 7, Bioinformatics Solutions) 50 . Spectra were also interpreted by de novo sequencing (PEAKS Studio 7, Bioinformatics Solutions) to improve high-confidence peptide identification. The msConvert program (version 3.0.45) was used to generate peak lists from the RAW data files, and spectra were then assigned to peptides using the SEQUEST (version 28.12) algorithm. RAW data files were imported into PEAKS Studio 7 before PEAKS DB and PEAKS de novo searching and subjected to default data refinement (deisotoping, charge deconvolution, peak centroiding). For all searches, the parent mass error tolerance was set to 20 p.p.m. and the fragment mass error tolerance to 0.02 Da. For SEQUEST and PEAKS DB, enzyme specificity was set to none and oxidation of methionines and deamidation (N, Q), cysteinylation, and phosphorylation (S, T, Y) were considered as variable modifications.
High-confidence peptide identifications were selected at a 1% false discovery rate with a version of the Percolator algorithm, which we modified for proteogenomic immunopeptide analysis 51 . Percolator implements a linear SVM (support vector machine) to score peptide identifications based on multiple peptide attributes. We modified the Percolator method to incorporate peptide attributes that influence the confidence in immunopeptide identifications. These included whether the de novo sequence matched database assignments; the magnitude of scores assigned by all three search algorithms; the source of the identified peptide (Swiss-Prot, TrEMBL, or our own sequencing); and the presence of one or more post-translational modifications in the identified peptide. Unlike conventional proteome analysis, false discovery rates were not evaluated at the level of assembled proteins, as this would have unnecessarily penalized proteins identified by small numbers of peptide. Confirmation of HLA identifications with synthetic peptides and mass spectrometry. Synthetic peptides corresponding to the idiotype peptides from MCL-41 (NMLFLQMNSLKTEDT, DDSKNMLFLQMNSLKTEDT, FLQMNSLKTEDT, IKNKIDGETTDYAAPV) were purchased from JPT Peptide Technologies (Berlin, Germany) with a purity of > 70%, dissolved, and resuspended into 0.1% formic acid. For each peptide, 250 fmol was analysed on an LTQ-Orbitrap Elite mass spectrometer (ThermoFisher, Bremen, Germany) using the same instrument settings as described above. Synthetic peptides were measured with two replicate LC-MS analyses, using either the CID or HCD fragmentation methods as defined above. Both included singly charged species. Quality assessment of HLA ligands. Sequence logos for recovered MHC-I peptides were produced using Icelogo (http://iomics.ugent.de/icelogoserver) to reveal position weighting at anchor residues 52 . The size distribution of recovered MHC-I and MHC-II bound peptides was compared with size distributions of known MHC-I and MHC-II ligands from the Immune Epitope Database and Analysis resource (http://www.iedb.org, January 2016) using filters for host (human) and assays (MHC ligand assays only) 53 . To assess compatibility of recovered MHC-I ligands with the netMHCpan 40 prediction algorithm, we tested cross-prediction for two patients with completely private HLA-A, -B, and -C alleles. Affinities for peptides recovered from one patient were predicted against self or unrelated HLA-A, -B, -C alleles.
Correlation of MHC presentation with gene expression.
To estimate gene expression, we used previous transcriptome profiling of MCL performed in ref. 20 . The median log 2 -transformed reads per kilobase of transcript per million mapped reads (RPKM) from the 15 patients from that study was used for predicted gene expression, and genes with a median log 2 (RPKM) > 0 were considered to be expressed. Every recovered MHC-bound peptide was assigned the log 2 (RPKM) of its corresponding gene. Total cell-line proteome sample preparation and high pH reversed-phase fractionation for MS-analysis. One hundred million cells from each of two MCL cell lines (JEKO and L128) were used for protein extractions. In brief, cells were lysed in 8 M urea, 150 mM NaCl, 5 mM DTT, 50 mM Tris pH 8 supplemented with Complete Protease Inhibitor Cocktail tablet (Roche) and 1× Halt Protease and Phosphatase Inhibitor Cocktail (ThermoFisher Scientific). After lysis, the lysate was centrifuged at 13,200 r.p.m. for 15 min, the supernatant was transferred to fresh tubes, and a second round of centrifugation was performed. The resulting supernatant was alkylated using 14 mM iodoacetamide for 45 min at room temperature in the dark and the reaction was then quenched with dithiothreitol (DTT). Proteins were methanol-chloroform precipitated and washed twice with acetone before being re-suspended in 300 μ l 8 M urea, 50 mM Tris pH 8. Total protein concentration was determined using a Pierce BCA Protein Assay Kit (Pierce, Rockford, Illinois, USA). The samples were diluted to 1 M urea using 50 mM Tris pH 8 before digestion with trypsin/Lys-C Mix (Promega, Madison, Wisconsin, USA) at a ratio of 1:25 enzyme:substrate for 16 h at 37 °C. The reaction was quenched with formic acid and the peptides de-salted using a Sep-Pak C18 1 cc Vac Cartridge, 50 mg (Waters, Milford, Massachusetts, USA). Digested peptides were re-suspended in 130 μ l 10 mM ammonium formate, pH 10, followed by high-pHRP fractionation 54,55 using a 65 min + 15 min step-gradient (buffer A (10 mM ammonium formate, pH 10) and buffer B (10 mM ammonium formate, 90% ACN, 10% H 2 O, pH 10)) using an Agilent 1200 HPLC (Agilent Technologies). In total, 84 fractions were collected, concatenated, and combined 55 into a total of 12 fractions and lyophilized by vacuum centrifugation. All fractions were cleaned using C18based STAGE Tips 48 , lyophilized, and stored at − 80 °C until final LC-MS/MS measurement. Mass spectrometry analysis of cell line proteomes. Each concatenated peptide fraction was re-suspended in 20 μ l 0.1% formic acid. In total 10% of the material was injected and separated on an 18 cm reversed-phase column (100 μ m inner diameter), packed in-house with ReproSil-Pur C18-AQ 3.0 m resin (Dr. Maisch GmbH) over a total run of 160 min using a two-step linear gradient with 4-25% buffer B (0.2% (v/v) formic acid, 5% DMSO, and 94.8% (v/v) acetonitrile) for 120 min followed by 25-40% buffer B for 30 min using an Eksigent ekspert nanoLC-425 system (SCIEX, Framingham, Massachusetts, USA). The LC system was coupled online with an Orbitrap Elite instrument (Thermo Fisher Scientific, Bremen, Germany) via a nano-electrospray source. Full scans were acquired in the Orbitrap mass analyser with resolution 60,000 at 340-1,600 m/z. Unassigned charge states were rejected and the top 20 most intense ions with charge states 2 and up were sequentially isolated for MS/MS analysis using CID fragmentation. A minimal signal of 500 was required, the normalized collision energy was set at 35%, and the fragmented peptide masses were collected in the ion-trap. Dynamic exclusion was enabled with a repeat count of 1 and the repeat duration set to 30 s. HLA-B*35 construct and genetic transduction of Raji cells. The cDNA sequence of full-length HLA-B* 35:01:01:01:01 was synthesized (IDT) with 25 base pairs of overlapping vector sequence on either end and cloned into pLenti-CMV-Puro-DEST (w118-1, a gift from E. Campeau) at the EcoRV sites using Gibson assembly (NEB). A two-step PCR was used to insert an N-terminal Flag tag downstream of the signal peptide. Lentivirus produced in HEK293FT cells was used to transduce Raji cells overnight. Transduced cells were selected by treatment with puromycin (1 μ g/ml, InvivoGen) for 7 days. Raji cells overexpressing the viral entry receptor DC-SIGN (a gift from E. Harris, University of California, Berkeley) with and without HLA* B35:01 overexpression were cultured in RPMI medium supplemented with 5% fetal bovine serum and 1× penicillin/streptomycin and l-glutamine. Computational interpretation of cell-line proteomes. Data were analysed with ProteomeDiscover version 2.1.0.81 (Thermo Fisher Scientific) and SEQUEST-HT with the following settings: the parent mass error tolerance was set to 20 p.p.m. and the fragment mass error tolerance to 0.6 Da. Strict trypsin specificity was required, allowing for up to two missed cleavages. Carbamidomethylation of cysteine was set as fixed modification and oxidation of methionines as a variable modification. The minimum required peptide length was set to seven amino acids. All spectra were queried in two independent searches against the patient-specific or the SNPderived databases as earlier described for the ligandome analysis. A false discovery rate of 1% was required at both the peptide level and the protein level. For each protein group, summed peptide intensities were used to estimate copies-per-cell abundance using the histone ruler approach 56 .
Three subsets of proteins were compared with the complete set of all recovered proteins: (1) proteins for which at least one corresponding peptide was recovered from the MHC-I immuno-peptidome dataset; (2) proteins for which at least one corresponding peptide was recovered from the MHC-II immuno-peptidome dataset; (3) proteins that were predicted to be mutated by exome sequencing and for which the predicted mutated peptide was identified by proteome analysis. The distributions of abundance for each of these subsets was compared with the distribution of all proteins using a two-tailed Kolmogorov-Smirnov test for each cell line, given the unequal variance between groups. Inter-patient similarity for MHC presentation of peptide and genes. The lists of unique peptides or genes presented by MHC-I and MHC-II for each patient were used to calculate inter-patient similarity. Peptides with a posttranslation modification were considered distinct from unmodified peptides (for example, a peptide with a phosphorylated residue was not identical to the same unphosphorylated peptide). The Sørensen similarity index was calculated between patients as 1 − (Bray-Curtis dissimilarity) using the R 'vegan' package based on peptide or gene similarity. A force-directed graph was generated based upon MHC peptide presentation similarity used in the R 'igraph' package. A weighted adjacency matrix was created and plotted with a Fruchterman-Reingold layout. For visualization, a minimum similarity of 0.15 was set as a threshold to produce an edge. HLA allele families for each patient were manually superimposed over the layout to highlight the relationship between peptide similarity and shared HLA alleles.
LETTER RESEARCH
The identified MHC-associated peptide repertoires showed relatively low inter-patient similarity (MHC-I: Sørensen similarity 0.01-0.45, median 0.12; MHC-II: Sørensen similarity 0.05-0.55, median 0.17), but similarity was increased between patients with shared or similar HLA alleles. Genes represented in the antigen repertoire were more similar between patients (MHC-I: Sørensen similarity 0.27-0.60, median 0.41; MHC-II: Sørensen similarity 0.04-0.48, median 0.26). Gene set enrichment of MHC-presented peptides. All recovered MHC-I bound peptides from all 17 patients were included. The total number of unique MHCpresented peptides recovered per gene was used to rank gene presentation. If an identical peptide was recovered from multiple patients, it was treated as an additional unique peptide mapping to that gene. The top fifth percentile of genes ranked in this manner were used for gene set enrichment analysed by the PANTHER statistical overrepresentation test 57 . Comparison of germline SNP peptide presentation versus somatically mutated peptide presentation. Germline SNPs for all 17 patients were identified as above. Recovered MHC-I-and MHC-II-associated peptides were matched with 100% identity against both the SNP variant allele and the corresponding reference allele as listed in hg19. Peptide expression of both alleles was considered true if peptides from both the SNP and corresponding reference allele were recovered in the same patient. The same analysis was performed for non-Ig somatic SNVs. No non-Ig somatically mutated peptides were presented by MHC-I or MHC-II. However, nine MHC-I peptides and nine MHC-II peptides from the corresponding germline allele were recovered, which overlapped the predicted mutated amino-acid position. A 2 × 3 Fisher's exact test was used to compare SNP recovery versus SNV recovery (where the three outcomes were recovery of variant peptide, recovery of the reference peptide, and recovery of both reference and variant peptide).
Comparison between Ig variable versus constant region presentation.
Unique MHC-presented peptides were aligned to the patients' IgVh and IgHμ (Ig heavy variable and heavy constant mu regions) sequences. IgVh sequences from all patients were aligned to each other using IMGT nomenclature and gap insertion when required for discrepant lengths. For each position on the Ig sequence, the numbers of unique peptides that overlapped that position were summed for all 17 patients and presented as a heatmap. The numbers of experimentally recovered peptides and the number of predicted peptides were determined for each position along the consensus Ig molecule. A two-sided Mann-Whitney-Wilcoxon test was used to compare the number of peptides per position for N-terminal (variable region plus N-terminal 50 amino acids of CH1) versus C-terminal (last 350 amino acids in constant regions) positions. This was performed separately for experimentally identified peptides and predicted peptides. Prediction of Ig presentation. The full-length Ig heavy-chain sequence for each patient was used as input into netMHCpan and predictions were performed for all peptides with a length of 8-11 amino acids for each of the patients' HLA-A, HLA-B, and HLA-C alleles. Two IC 50 thresholds were evaluated: 50 nM and 500 nM. For each Ig position, a patient was counted as presenting that position if at least one peptide spanning it was predicted to meet the threshold for self-MHC prediction. The number of patients with predicted presentation of that position was then summed, with a maximum value of 17 patients presenting a position.
We evaluated whether the reduced MHC-I presentation of the N-terminal 170-amino-acid region of the heavy chain (corresponding to the variable region plus N-terminal portion of the CH1 constant domain) was related to differences in the predicted presentation between this region and the rest of the constant regions. Peptide-MHC binding predictions were performed as above for each patient's Ig heavy-chain sequence. The total number of predicted peptides for each position was summed across all 17 patients for the N-terminal 170 amino acids and the C-terminal 400 amino acids. HLA-DR tetramer preparation. A baculovirus construct encoding Jun/Fos dimerization domain-modified HLA-DRB1* 04:01 with tethered CLIP peptide was used to produce DR4 protein in insect cells. The product was FPLC purified, biotinylated, and peptide exchanged as described in ref. 58 . Candidate peptides predicted to interact with DR4 were assayed for binding by flow cytometry, and those that successfully exchanged into the peptide-binding groove were used in subsequent class II tetramer studies. Peptide-MHC monomers were tetramerized using phycoerythrin (PE)-or allophycocyanin (APC)-linked streptavidin (eBioscience), and residual non-tetramer components were eliminated with biotin agarose (Sigma) and streptavidin agarose (ThermoFisher). The peptides used in this study were MCL008_IgK1 APRLLIYDAANRATG, MCL008_IgH1 KNQFSLELNSVTAADTA, MCL034_IgH1 GQVTISVDKSISTAYL, MCL041_ IgH1 NMLFLQMNSLKTEDT, MCL041_IgH2 IKNKIDGETTDYAAPV, and MCL041_IgH3 DDSKNMLFLQMNSLKTEDT. To test binding affinity to HLA-DR, peptides were also synthesized with an N-terminal dinitrophenyl (DNP) modification. After exchanging the peptides into HLA-DR as described above, the biotinylated HLA-DR molecules were bound to streptavidin-coated microsphere beads and co-stained with both anti-HLA-DR and anti-DNP antibodies. Beads were then analysed by flow cytometry. One peptide that was not computationally predicted to bind either of the patient's HLA-DR alleles (IKNKIDGETTDYAAPV) was found to have high affinity for HLA-DR* 0401, highlighting the sensitivity of proteomic methods for MHC ligand discovery. HLA-DR tetramer staining and single-cell sequencing. Total peripheral blood mononuclear cells (PBMCs) or purified CD4 + T cells were treated with 50 nM dasatinib (CST) for 30 min at 37 °C to inhibit TCR downregulation. Samples were then stained with tetramers (0.5 μ g/ml each specificity) and Fc block for 1 h at room temperature, with agitation. Antibodies and live/dead staining reagents were added during the last 30 min of tetramer staining. Samples were washed, and tetramer-positive CD4 T cells (and tetramer-negative control cells) were single-cell sorted with a FACSAria sorter (BD Biosciences). The TCR and select phenotypic mRNA were amplified from each cell by nested PCR, the products were pooled and purified, and sequenced using Illumina MiSeq as previously described 22 . For single-cell sequencing, reads were assembled, de-barcoded, and TCR α -and β -chains were called for each cell that met acceptable confidence thresholds using a customized pipeline 22 . For phenotyping analysis, cells with at least ten reads of a particular mRNA were considered positive. TCR-β repertoire sequencing. DNA was extracted from peripheral blood mononuclear cells, then TCR-β CDR3 regions were amplified and sequenced using ImmunoSEQ (Adaptive Biotechnologies, Seattle, Washington, USA) from 400 ng of DNA template 59 . Bias-controlled V and J gene primers were used to amplify rearranged V(D)J segments for high-throughput sequencing at ~ 20× coverage. After correcting sequencing errors via a clustering algorithm, CDR3 segments were annotated according to the International ImMunoGeneTics collaboration, identifying which V, D, and J genes contributed to each rearrangement 60 . HLA-A2 tetramer staining and preparation. HLA-A02:01 tetramers containing an ultraviolet-cleavable peptide 61 were synthesized by the NIH Tetramer Facility. Potential HLA-A2-binding (predicted IC 50 < 500 nM by netMHC 62 ) neoantigen peptides from eight patients with HLA-A2 were synthesized (Sigma-Aldrich or JPT Peptide Technologies), exchanged, and multimerized with streptavidin-PE as previously described 63 . Vaccine-primed PBMCs were collected by apheresis. Cells were pre-treated with 50 nM dasatinib for 60-180 min. To determine background staining, we used T cells from leukocyte reduction system cones from two or three healthy HLA-A2 donors from the Stanford Blood Center. These cells were barcode-labelled with distinct levels of CellTrace Violet dye (ThermoFisher) to enable multiplexing. Donor cells were treated with dasatinib in parallel and then pooled with T cells from patients immediately before tetramer staining. Cells were mixed so that the total number of pooled healthy donor cells equalled that of the patient's T cells. Background staining was determined as the highest frequency seen in a single donor. Tetramer staining was otherwise performed as previously described 63 . HIV-gag SLYNTVATL peptide was used as a negative control, and CMV-pp65 NLVPMVATV and Flu-M1 GILGFVFTL peptides were used as positive controls.
Neoantigen T-cell purification and expansion. Patient leukocytes were collected by leukapheresis approximately 2 weeks after the series of autologous tumour vaccinations. CD4-expressing T cells were purified by negative magnetic bead selection using a MACS CD4 + T-cell isolation kit (Miltenyi Biotec). CD4 T cells were co-incubated with autologous PBMCs collected at a later time, at a ratio of 1:1. Cells were cultured in a 1:1 mix of AIM-V media and RPMI1640 (Thermo Fisher) with 10% autologous plasma and 50 μ M β -mercaptoethanol. Neoantigen peptides or matching germline peptides were synthesized (ElimBio) and added to a final concentration of 10 μ g/ml. For each of the three MHC-II peptide families sharing a core sequence, a single 29-to 30-amino-acid peptide was constructed with the shared core sequence in the centre. As a positive control, cells were stimulated with a mixture of pathogen-associated peptides, CEFT pool (JPT Peptide Technologies). Cells were incubated for 30 h before FACS sorting. Cells were sorted on live, CD4 + , CD137 + cells using a FACS Aria sorter (BD Biosciences). A total of 278 neoantigen-specific cells were collected and co-cultured with a pooled mix of 50,000 feeder PBMCs from three irradiated (40 Gy) allogeneic healthy donors in 1:1 AIM-V/RPMI media with 10% pooled human AB sera (Gemini Bio), β -mercaptoethanol, 30 ng/ml anti-CD3 antibody (OKT3, eBiosciences), 1 μ g/ml anti-CD28 antibody (CD28.2 eBiosciences), and 10 U/ml recombinant human IL-2 (Peprotech). Media were supplemented every 1-3 days with media containing fresh IL-2 and β -mercaptoethanol. Every 7 days, cells were co-incubated with fresh irradiated allogeneic feeder cells, anti-CD3 antibody, and anti-CD28 antibody. Confirmation of neoantigen T-cell specificity. After ~ 2.5 weeks of expansion, a fraction of the T-cell culture was rested for 5 days in 1:1 AIM-V/RPMI media with 10% pooled human AB sera (Gemini Bio), β -mercaptoethanol, but lacking feeder cells, anti-CD3, anti-CD28, or rhIL-2. The T-cell cultures were labelled with CellTrace Violet (Thermo Fisher), incubated with autologous PBMCs loaded with a mix of pathogen-derived peptides, or a pool of neoantigen peptides, or a pool
